For the development of next-generation antibodies and ADCs, this review focuses on the lessons learned with the well-studied tumor antigen human epidermal growth factor receptor 2 (HER2) by describing the reports that investigate internalization and accumulation with approved and investigational HER2-specific antibodies and ADCs. This evidence concerns the gene ERBB2 and neoplasm.